Development and Validation of a Microdissection Method to Advance Precision Medicine in the Clinical Setting

显微切割方法的开发和验证在临床环境中推进精准医学

• 批准号: 9035128
• 负责人: Donald Johann
• 金额: $ 41.07万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9035128
• 关键词: Biological Assay; Breast; Cancer Biology; Cancer Diagnostics; Cancer Patient; Cell Separation; Cells; Characteristics; Clinical; Clinical Oncology; Clinical Trials; Collection; Colon; Common Neoplasm; DNA; Development; Disease; Dissection; Evaluation; Formalin; Generations; Genomics; Immunohistochemistry; Lasers; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Manuals; Methodology; Methods; Microdissection; Molecular; Molecular Analysis; Molecular Profiling; Neoplasms; Paraffin Embedding; Pathologist; Pathology; Patient Rights; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Physicians; Population; Population Heterogeneity; Procedures; Process; Proteins; Proteomics; Public Health; RNA; Reporting; Reproducibility; Research Personnel; Role; Sampling; Solid Neoplasm; Specificity; Specimen; Speed; Supervision; Technology; Testing; Time; Tissues; Treatment outcome; Validation; base; cancer therapy; cell type; diagnostic assay; functional genomics; histological slides; improved; improved outcome; individual patient; innovative technologies; instrument; interest; molecular diagnostics; neoplastic cell; precision medicine; public health relevance; research study; tool; transcriptomics; treatment planning; treatment strategy; tumor

 DESCRIPTION (provided by applicant): Precision medicine can impact the treatment of cancer by identifying the right drug at the right time for the right patient. However, current fron-end pathology tools are insufficient for today's sophisticated functional genomic tests. In order t improve patient outcomes, we propose to advance an innovative technology, Expression Microdissection (xMD) that utilizes standard immunohistochemistry to easily and rapidly isolate pure tumor cell populations from heterogeneous tissue sections. In our proposal, we aim to clinically validate xMD technology on common tumor types by assessing dissection efficiency, specificity, and reproducibility, and to establish standard operating procedures (SOPs) for the xMD process. We will also evaluate the quality of the recovered DNA, RNA and protein and assess the effect of xMD on assay results. Finally, we will study a set of lung cancer specimens to evaluate the robustness of xMD and generate a comprehensive patient report detailing the molecular profile of each patient specimen.